MiMedx Group (MDXG) Fundamentals 2026 — P/E 20.3x, Revenue Analysis | SniperIQ
MiMedx Group (MDXG) is a US-listed Healthcare company in Biotechnology with a market capitalization of $621M, trading at $4.17 on the NASDAQ. This SniperIQ fundamentals page covers MiMedx Group's valuation (P/E 20.3x, P/B 2.5x), profitability (net margin 7.9%), revenue ($419M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is MiMedx Group's market cap?
MiMedx Group (MDXG) has a market capitalization of approximately $621M, trading at $4.17 on the NASDAQ. Market cap moves with the live share price.
What is MiMedx Group's P/E ratio?
MiMedx Group's trailing twelve-month P/E ratio is 20.3x, with a price-to-book (P/B) of 2.5x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is MiMedx Group?
MiMedx Group runs a net profit margin of 7.9%, a gross margin of 81.0%, and an operating margin of 10.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does MiMedx Group generate?
MiMedx Group reported revenue of $419M for fiscal year 2025, with net income of $49M and earnings per share (EPS) of 0.33. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does MiMedx Group pay a dividend?
MiMedx Group does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is MiMedx Group financially healthy?
MiMedx Group carries a debt-to-equity ratio of 0.07x and a current ratio of 5.39x, with a market beta of 1.45. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is MiMedx Group a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For MiMedx Group (MDXG) the key facts are: market cap $621M, P/E 20.3x, revenue $419M, 52-week range 3.03-7.99. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track MiMedx Group's full fundamentals live
Get MiMedx Group's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.